Altavant Sciences Details Its ‘Patient-centric’ Approach to PAH Clinical Trials

Altavant Sciences Details Its ‘Patient-centric’ Approach to PAH Clinical Trials

Altavant Sciences presented its patient-centered approach to drug development, which informed the design of an ongoing Phase 2 study, at the Pulmonary Hypertension Association’s recent Annual PH Professional Network (PHPN) Symposium.

The effort was detailed in the poster “A Framework for Engaging PAH Patients in the Drug Development Process” given at the Washington, D.C., meeting.

Altavant is developing rodatristat ethyl (also known as RVT-1201), as a possible therapy for pulmonary arterial hypertension (PAH). Rodatristat ethyl works by lowering the levels of serotonin, a hormone known to send signals that raise blood pressure.

Preliminary studies in healthy volunteers showed a good safety profile.

Altavant recently launched a Phase 2 clinical trial (NCT03924154), called ELEVATE 1, testing rodatristat ethyl in PAH patients. The study is currently enrolling up to 36 patients at sites in the U.S. and Canada; information is available here.

Discuss the latest research in the Pulmonary Hypertension News forums!

According to the company, patients were at the forefront in developing ELEVATE 1’s protocol.

“We believe that patient involvement in the clinical trial design and implementation process is crucial in the development of new medicines,” William T. Symonds, PharmD, the chief executive officer at Altavant, said in a press release.

This trial design approach includes conducting interviews and surveys to gather information about patients’ actual experiences. It also provides relevant educational content so that patients can make better informed healthcare decisions.

The strategy goes beyond strictly health-related topics, noting the importance of trial participants. Each is sent a thank-you card to participants, and are referred to as “study volunteers” rather than “subjects.”

Altavant also partners with Greater Gift, donating a vaccine to a person in need in honor of each trial participant.

“Published literature suggests that trials designed with patient input enroll faster, potentially lowering development costs,” Symonds said. “In addition, patient feedback is more positive and retention is greater compared to industry standards.

“We look forward to implementing these patient-centric practices across our development programs, and evaluating their impact,” he added.

The company also plans to expand its patient-centered approach by engaging with PAH patients through social media, advisory boards, and advocacy organizations to have their input in future clinical development work.

“A framework for clinical trial patient engagement that takes patient needs and experiences into consideration, and guides interactions may ignite the PAH patient community interest in clinical research, and speed up development of new medicines,” researchers concluded in the poster.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 329
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • pulmonary hypertension, Adcirca
  • patient-centric approach
  • UW Medicine lung transplant
  • blood biomarkers
Average Rating
0 out of 5 stars. 0 votes.
My Rating:

Leave a Comment

Your email address will not be published. Required fields are marked *